Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Backers
2
RA Capital Management, Deerfield Management
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Slate MedicinesSeries A $130M · 7 mo ago • Founded 2024 • 51-200 employees
We’re building a pipeline of next-generation therapeutics focused on broadening the treatment paradigm for migraine and other headache…
OrikineFounded 2022 • 201-500 employees
Precision-engineered, bi-specific cytokines to treat autoimmune and inflammatory diseases. Highly versatile protein-design platform to…
Bright Peak TherapeuticsSeries C $90M · 2 yr ago • Founded 2012
Creating next generation immunotherapy treatments for cancer and autoimmune disease.
SynoloFounded 2023 • 1-10 employees
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.
cAMPfield TherapeuticsFounded 2026 • 3 roles
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
Atavistik BioSeries B $120M · 9 mo ago • Founded 2021 • 51-200 employees • 1 role
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…

Overview

Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.